Due to various advantages like patient preference and ease of administration, oral biologics are preferred over other methods. The Oral biologics market is majorly driven by the prevalence of cardiometabolic diseases and rheumatoid arthritis, acquisition and mergers between the companies, approvals from the government authorities.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32907
According to a 2020 report of Arthritis Foundation, 1 in 3 individuals between the age group of 18-64 have arthritis in U.S. Cardiometabolic diseases include chronic renal failure, cardiovascular disease (CVDs) and diabetes mellitus. These diseases are the leading cause of death globally.
According to WHO report 2019, 17.9 million died due to CVDs, accounting for 32% of global deaths. This acts as a driver for the oral biologics market. The oral biologics market is also driven by the increase in FDA approvals for oral biologics.
For instance, in 2019, FDA approved Novo Nordisk’s oral biologics, Semaglutide, for the treatment of type 2 diabetes. Moreover, an increase in the awareness about oral biologics and R & D investment by the companies for developing new techniques is expected to increase demand for oral biologics during the forecast period.
Get A Customized Scope To Match Your Need Ask An Expert – sales@persistencemarketresearch.com
- Lumen Bioscience Inc.
- Novo Nordisk A/S
- Lilly
- Rani Therapeutics
- Biocon Limited
- Pfizer Inc.
- BeiGene
- EnteraBio Ltd
- AbbVie Inc.
The market players are involved in acquisitions and mergers. For instance, in 2020, Novo Nordisk A/S acquired Emisphere Technologies, a drug delivery company.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32907
Another region that is expected to dominate the market is Europe followed by Asia. This is due to the presence of manufacturing companies some players in this region and new product launches are expected to drive the market.
Key Segments
By Drug class
- Tumour necrosis factor-alpha inhibitors
- Lymphocyte modulators
- Interleukin inhibitors
By Indication
- Rheumatoid Arthritis
- Psoriasis
- Inflammatory bowel disease (IBD)
- Ulcerative colitis
- Cardiometabolic disease
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32907
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com